3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
53
Lymphoma, Mantle-Cell
31
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Non-Hodgkin
14
Lymphoma
11
Leukemia, B-Cell
6
Lymphoma, Follicular
5
Lymphoma, B-Cell, Marginal Zone
5
Lymphoma, B-Cell
5
Leukemia
5
Waldenstrom Macroglobulinemia
4
Multiple Myeloma
3
Recurrence
2
Pancreatic Neoplasms
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Prolymphocytic
2
Hematologic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Pyloric Stenosis, Hypertrophic
1
Part1: Advanced B-cell Malignancies
1
Ovarian Neoplasms
1
Neuritis
1
Neoplasms
1
Neoplasm, Residual
1
Leukemia, Hairy Cell
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Hematologic Diseases
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
93
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
51
Doxorubicin
50
atezolizumab
48
trametinib
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
acalabrutinib
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled